大麻二酚治疗胃排空正常的功能性消化不良:一项随机对照试验
本研究为随机双盲安慰剂对照试验,比较药用级大麻二酚(CBD)与安慰剂治疗4周对胃排空正常的FD患者的药效学和临床效果,并评估FAAH与CNR1基因变异对CBD效果的影响。结果显示CBD与安慰剂在生理功能和患者应答结局上无显著差异,存在临界性的CBD治疗与基因型交互作用。
要点
- CBD与安慰剂对胃排空正常FD患者的生理功能和症状应答无显著差异。
- CBD治疗与CNR1 rs806378在餐后窘迫综合征量表上存在临界交互作用(P=0.06)。
- CBD治疗与CNR1 rs806378在固体胃排空上存在临界交互作用(P=0.12)。
核心结论
- 超说明书使用已批准剂量的CBD不能缓解基线固体胃排空正常的FD,也不改变胃运动功能和饱感。
- CBD治疗与基因交互作用提示对CNR1 rs806378 T等位基因携带者的餐后窘迫可能有益。
研究设计与样本
- 随机、双盲、安慰剂对照(1:1比例)研究。
- 对象为基线胃排空非延迟的功能性消化不良患者。
- CBD每日两次给药,按美国食品药品监督管理局递增指导为20 mg/kg/d。
- 治疗4周后所有患者接受固体胃排空、胃容量和Ensure营养饱感测试。
主要发现
- CBD与安慰剂对生理功能和患者应答结局的影响无显著差异。
- CNR1 rs806378与鲁汶餐后窘迫量表的CBD治疗与基因型交互作用P=0.06。
- CNR1 rs806378与固体胃排空的CBD治疗与基因型交互作用P=0.12。
关键数值与推荐
- 症状评估采用经验证的每日症状日记(上腹痛、恶心、腹胀采用0-4分量表)。
- 每周评估充分缓解,采用鲁汶餐后窘迫量表(8个症状,形容词严重程度评分0-4分)。
- 生活质量采用Short-Form Nepean消化不良指数(10个维度各5分制取平均值)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cannabidiol (CBD), a CBR2 agonist with limited psychic effects, antagonizes CB1/CB2 receptors. Allelic variation CNR1 (gene for CBR1) rs806378 and FAAH rs324420 were associated with altered gut motility and sensation. This study aimed to compare the pharmacodynamics and clinical effects of a 4-week treatment with pharmaceutical-grade CBD vs placebo and assess the interactions of FAAH and CNR1 gene variants on the effects of CBD in patients with functional dyspepsia (FD). METHODS: We performed a randomized, double-blinded, placebo-controlled (1:1 ratio) study of CBD b.i.d. (20 mg/kg/d according to the US Food and Drug Administration escalation guidance) in FD patients with nondelayed gastric emptying (GE) at baseline. Symptoms were assessed by validated daily symptom diary (0-4 scale for upper abdominal pain, nausea, and bloating), weekly assessment of adequate relief, Leuven Postprandial Distress Scale (8 symptoms, adjectival scores rated 0-4 for severity), and quality of life (Short-Form Nepean Dyspepsia Index [average of 10 dimensions each on a 5-point scale]). After the 4-week treatment, all patients underwent measurements of GE of solids, gastric volumes, and Ensure nutrient satiation test. Statistical analysis compared 2 treatments for all endpoints and the effects of CBD in association with FAAH rs324420 and CNR1 rs806378. RESULTS: CBD and placebo effects on physiological functions and patient response outcomes were not significantly different. There were borderline CBD treatment-by-genotype interactions: rs806378 CNR1 with Leuven Postprandial Distress Scale ( P = 0.06) and GE solids ( P = 0.12). DISCUSSION: Approved doses of CBD used off-label do not relieve FD with normal baseline GE of solids or alter gastric motor functions and satiation. CBD treatment-by-gene interactions suggest potential benefits for postprandial distress with CNR1 rs806378 T allele.
引用
- Atieh J, Maselli D, Breen-Lyles M, et al. Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial. Am J Gastroenterol. 2022. PMID: 35537858. doi:10.14309/ajg.0000000000001805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。